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versus placebo. Significant improvements were evident at Week-4 and main-
tained through Week-12.
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OBJECTIVES: Few studies have evaluated the impact of GERD-symptoms on
work productivity and no French data are available. The aim of this study was to
evaluate the impact of GERD typical symptoms on work productivity and daily
activities in patients with nocturnal compared to diurnal symptoms. METHODS:
A prospective, multicenter, observational study was carried out in French pri-
mary care setting. Each physician had to include the first two consecutive adult
patients on full-time job who had experienced GERD typical symptoms at least
once during the 7 days/nights preceding the inclusion visit: 1 with exclusively
diurnal symptoms and 1 with nocturnal symptoms. Data collected by physi-
cians were: patients’ characteristics, symptomatology and treatments. Work
productivity loss was assessed using the validated self-administered Work Pro-
ductivity and Activity Impairment questionnaire specific to GERD (WPAI-GERD).
Predictors of work productivity loss were identified by multivariate regression
models and its cost estimated. RESULTS: A total of 407 physicians included 716
eligible patients: 50.8% with nocturnal and 49.2% with exclusive diurnal symp-
toms (EDS). The mean age was 46.3 years (SD 8.7), 62.8% were men, and 58.3% of
patients diagnosed before inclusion were treated for GERD. Work productivity
and daily activities decreased by 31.4% and 32.6%, respectively. Decrease rates
were higher in EDS-patients (p0.001 each). Work productivity impairment was
mostly due to impairment while working (presenteeism) rather than absentee-
ism. The symptoms intensity and composite intensity index, reflecting disease
severity, were identified as the main predictors of decreased work productivity.
The mean cost of work productivity loss per patient was estimated as €313/
week, also higher in EDS-patients (p0.001). CONCLUSIONS: GERD incurs high
work productivity loss which yields a substantial burden. Improving patients’
outcomes, especially in those with moderate or severe disease, with most ef-
fective tailored treatments and care management could be expected to reduce
work productivity loss and associated costs.
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OBJECTIVES: To assess average direct medical costs of treatment of consecutive
stages of HCV in Poland. METHODS: A questionnaire study in 7 medical centres
among experienced clinicians (1200 patients managed annually in total) was per-
formed. Six separate questionnaires were prepared and initially validated for de-
fined HCV health states: mild hepatitis-MiH, moderate hepatitis-MoH, compen-
sated cirrhosis-CoC, decompensated cirrhosis-DeC, hepatocellular carcinoma-
HCC and post liver transplant phase–1st (PLT1) and 2nd(PLT2) year of follow-up.
Each professional was asked for describing a typical procedures set conducted in
an theoretical average patient in specified chronic hepatitis C health state. The
procedures sets consisted of a few main categories: hospitalisation, ambulatory
care, diagnostic procedures, pharmacotherapy, rehabilitation, adequately to dis-
ease phase and in accordance with official procedures lists published by National
Health Fund for 2011. Antiviral treatment was excluded from the analysis.
RESULTS: Five questionnaires for each of mild hepatitis, moderate hepatitis, com-
pensated cirrhosis, decompensated cirrhosis, and two for HCC and post liver trans-
plant health states, were obtained. Calculated mean annual costs of defined health
states and their relation to the cost of liver transplantation in Poland (200000PLN
48000€ in 2010) are as follow: MiH with SVR–422PLN (99€), 0,2%; MoH with SVR–
800PLN (188€), 0,4%; CoC with SVR–2018PLN (475€), 1,0%; MiH no SVR–2384PLN
(561€), 1,2%; MoH no SVR–3097PLN (729€), 1,5%; CoC no SVR–4995PLN (1175 €), 2,4%;
DeC–14860PLN (3496€), 7,3%; HCC–38927PLN (9159€), 19,0%; PLT1–30626PLN (7206€),
15,0%; PLT2–19973PLN (4699€), 9,8%. CONCLUSIONS: There is a marked increase of
mean annual costs of standard treatment of HCV patients along with disease stage.
Assuming that in Poland about 700000 individuals can be infected with HCV, most
of them being unaware of the disease, high costs of complications of chronic hep-
atitis-C are serious social and economic burden. National screening programme
with effective antiviral treatment at early stages of disease can reduce this negative
impact on society.
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OBJECTIVES: To understand resource utilization and costs associated with refer-
rals and testing for patients with irritable bowel syndrome with constipation
(IBS-C) based on treatment response. METHODS: A web-based survey was con-
ducted for a sample of primary care physicians (PCPs) and gastroenterologists (GEs)
across different US regions. The survey captured data on referral patterns (to/from
gastroenterologists), test/procedure ordering, and follow-up physician visits for
typical patients who did and did not achieve a satisfactory relief of symptoms to a
recent treatment for IBS-C (“response”). Survey items included questions regarding
the proportion of patients who would receive tests/procedures and follow-up phy-
sician visits. Health care costs were estimated by applying associated unit costs
(derived from the 2012 Medicare physician payment schedule) to the correspond-
ing utilization. All patients were assumed to begin treatment with PCPs. The cost of
treatment failure was defined as the cost difference between physician-deemed
non-responders and responders, incorporating both PCP work-up costs and the
costs of referrals to GEs. RESULTS: Twenty PCPs and 21 GEs completed the survey.
Mean monthly number of adults treated by the physicians was 61. Most non-re-
sponders (median: 80%; mean: 72%) would be referred to a GE by PCPs. Non-re-
sponders would be more likely to receive a test/procedure compared to responders
(median: 75 vs. 0% for PCPs; 50 vs. 0% for GEs; mean: 65 vs. 10% for PCPs; 56 vs. 33%
for GEs). Thyroid function tests, complete blood count, and colonoscopy were the
most common tests/procedures that would be ordered, by both PCPs and GEs. The
median (mean) expected cost of treatment failure was estimated to be $825 ($613).
CONCLUSIONS: Not responding to treatment may result in referral to a specialist
and/or additional testing and procedures, which may lead to higher health care
resource use and costs among patients with IBS-C, a finding of potential interest to
payers.
GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: To assess the impact of treatment response on quality of life (QOL)
and work productivity for patients with irritable bowel syndrome with constipation
(IBS-C). METHODS: Irritable Bowel Syndrome - QOL (IBS-QOL) score, EQ-5D index
score, work productivity, and IBS symptom relief were collected in two phase III
randomized placebo-controlled clinical trials of linaclotide, an investigational
treatment for IBS-C. Treatment response for IBS-C was defined as (1) a  14-point
increase at Week 12 from baseline on the overall IBS-QOL score or (2) moderately or
significantly relieved on a seven-point Likert scale on global symptom relief for 2
out of 3 months. Hours of work missed due to IBS-C were collected using the Work
Productivity and Activity Impairment (WPAI) Questionnaire. Data from the intent-
to-treat populations were pooled for linaclotide and placebo across two trials.
EQ-5D index score and work productivity were evaluated among responders and
non-responders. RESULTS: Patients were analyzed with available EQ-5D and IBS-
QOL data (n1,487) and available EQ-5D and IBS symptom relief data (n1,558),
with response rates of 46% and 14% respectively. Patients were analyzed with
available WPAI and IBS-QOL data (n1,056) and WPAI and IBS symptom relief data
(n1,103), with response rates of 47% and 15%, respectively. Responders had sta-
tistically significantly higher EQ-5D scores at Week 12 than non-responders, for
both definitions (IBS-QOL: 0.85 vs. 0.81, IBS symptom relief: 0.91 vs. 0.81, both
P0.05). Responders were statistically significantly less likely to miss 1 hour of
work during 12 weeks for IBS-C (IBS-QOL: 16.0% vs. 21.7%, IBS symptom relief: 9.6%
vs. 20.8%, both P0.05). CONCLUSIONS: Improvements in disease-specific mea-
sures correlate with improvements in health utilities and reduced work absentee-
ism among patients with IBS-C.
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OBJECTIVES:Despite Italy has a large HCV infected pool (1.500.000 estimated) novel
Direct Antiviral Agents (DAAs) against HCV genotype 1 have not yet been approved.
As the estimated budget to cover all eligible patients could be ten-fold higher,
limitations or patient selections could be applied. The study purpose is to obtain
the patients’point of view about associated costs, sustainability, possible scenarios
related to the lack of economic resources. METHODS: EpaC is the most important
Italian NGO for HCV patients. An anonymous web-based questionnaire was pub-
lished on the association website www.epac.it. It was composed of multiple choice
questions and was preceded by a scenario reporting a mean drug cost per patient
per course of 25.000-35.000 €, the availability of interferon-free monotherapy DAAs
drugs in the nearest future, different reimbursement possibilities (payment-by-
results, expenditure thresholds . . .). RESULTS: A total of 763 patients participated
the survey and 727 questionnaires were considered validly compiled. The profile of
the participants was assessed concerning sex, age, geographical provenience,
health condition, fibrosis stage, eligibility for triple treatment. 83% of patients
claimed equity of access independently of disease severity, 55% is not inclined to
postpone the treatment despite 62% of these has low/medium fibrosis, 77% of
participants does not tolerate the lack of resources that could lead to patient se-
lection, 40% is disposed to travel anywhere to get the most appropriate therapy.
CONCLUSIONS: This was a unique and the largest survey on Italian patients about
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this topics and its results express patients’ determination in looking for specialized
structures having funds for cures, which could lead to important internal and
external migration flows. Patients expect from EpaC to raise awareness in the
policy makers on the need for approval of the new DAAs and to bring on a campaign
of novel therapies equity of access with all Institution independently from the
severity of disease stage.
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OBJECTIVES: To develop a self-report questionnaire to evaluate gas-related symp-
toms (bloating, flatulence, belching, stomach rumbling and bad breath) and their
impact on daily life for Irritable Bowel Syndrome (IBS) patients and healthy subjects
complaining of gas-related symptoms. METHODS: A literature review and gastro-
enterologist interviews (n6) supported development of a preliminary conceptual
framework which was discussed with and validated by an international expert
committee. Then, semi-structured focus groups and face-to-face interviews with
IBS patients (n28) and healthy subjects (n27) complaining of gas-related symp-
toms were conducted in France, Spain and the UK. Qualitative analysis confirmed
the questionnaire conceptual framework, which was finalized with the expert
committee. Questionnaire items were generated simultaneously in French, Span-
ish and UK English, with item content based on subjects’ quotations. Iterative
rounds of cognitive debriefing interviews with IBS patients (n15) and healthy
subjects (n15) were subsequently conducted to assess questionnaire understand-
ing, acceptability and content validity across countries. RESULTS: Eight gas-related
symptoms (bloated feeling, distension, flatulence, and odorous flatulence, sensa-
tion of difficult gas evacuation, stomach rumbling, belching and bad breath) were
identified and described by the subjects in terms of severity and/or duration. Qual-
ity of life domains impacted by these symptoms were: emotional, clothing, diet,
cognitive function, physical appearance, social life, work life, sleep, sexual life,
physical activity, activities of daily living and partner relationships. Both a 24-hour
recall symptom diary (18 items) and a 7-day recall impact questionnaire (26 items)
were generated supported by the qualitative findings. Comprehension testing to
confirm the relevance and understanding of the instruments is on-going.
CONCLUSIONS: The questionnaires were developed following a rigorous method-
ology based on comprehensive qualitative research. Both gas-related symptoms
and their associated impact are assessed in a manner appropriate for two popula-
tions. This makes it a unique tool to be included in clinical programs. The next step
is to perform psychometric validation.
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OBJECTIVES: Research into the impact of Crohn’s Disease (CD) and its treatment
on the patient is reliant on dated generic questionnaires of limited relevance.
These measures ask questions of limited relevance to the population and miss
crucial aspects of the illness experience. As part of a study to develop CD-
specific patient-reported outcome (PRO) measures, qualitative interviews were
conducted with CD patients in order to model the impact of the disease on the
patient. METHODS: Interviews were conducted with CD patients recruited from
out-patient clinics. The interviews, which took the form of focused conversa-
tions covering all aspects of the impact of CD and its treatment, were audio-
recorded. The interview transcripts were analysed to identify the symptoms,
activity limitations and QoL impairments resulting from CD. This analysis em-
ployed the WHO International Classification of Functioning, Disability and
Health (ICF) and the needs-based quality of life (QoL) model. RESULTS: Thirty
patients (60% female; aged 25-68; mean (SD): 47.9 (14.3) years) were interviewed.
Participants had a wide range of CD duration (2-40; mean (SD): 14.3 (13.4) years).
Nearly 3,000 statements relating to the impact of CD were identified. These fell
into 3 major categories; symptoms (including pain, fatigue and emotional im-
pairment), activity limitations (examples; walking, lifting and jobs around the
house) and QoL. Needs affected by CD included autonomy, preoccupation with
CD, self-consciousness and reduced socialisation. CONCLUSIONS: The findings
from the interviews indicate that CD has three major types of impact; symp-
toms, activity limitations and QoL. All three should be addressed in CD audit,
clinical trials and when evaluating clinical practice. Items generated from the
interviews will be used to form a new suite of PRO measures specific to CD.
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OBJECTIVES: Patients with hemophilia A and inhibitors are at high risk for severe
bleeding and progression of joint disease with consequent deterioration of their
health-related quality of life (HRQoL). The Pro-Feiba Study was designed to assess
clinical and quality of live outcomes comparing prophylaxis to on demand therapy.
METHODS:A prospective, randomized, crossover study (Pro-FEIBA Study) aimed to
evaluate safety, efficacy and HRQol of AICC for bleeding prophylaxis in hemophilia
A patients 2 years with high-responding inhibitors. The study compared 6
months of AICC prophylactically dosed at 85 U/kg15% on 3 non-consecutive days
per week with 6 months of on-demand therapy (85 U/kg15%). The 2 study periods
were separated by a 3-month washout (patients used on-demand therapy). Quality
of life in patients 14 years was assessed at the beginning and end of each study
period with 2 generic instruments: the Short-Form 36 (SF-36) and the EQ-5D.
RESULTS: Nineteen subjects, of 26 valid patients , were 14 years and potentially
evaluable for HR-QoL. Of these, 18 patients (mean age: 32.6 years; min-max: 16.1-
62.8) completed SF-36 and/or EQ-5D questionnaires at each time point. Sixteen
patients completed both the SF-36 and the EQ-5D at the beginning and end of each
study period, 1 patient completed only the SF-36, and 1 patient completed only the
EQ-5D. A comparison of the 2 periods showed a trend towards HRQoL improvement
favouring prophylaxis. Differences between the 2 study period for SF-36 physical
component summary (PCS) were statistically significant in “good responders”
(50% bleeding episodes reduction) (p0.018). PCS differences were statistically
significant in all evaluable subjects when measured before and after prophylaxis
(p0.047). The EQ-5D health profile showed an improvement trend toward
prophylaxis. CONCLUSIONS: AICC prophylaxis significantly improved HRQoL as
compared with episodic treatment. Larger cohorts and longer follow-up are neces-
sary to confirm these data.
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OBJECTIVES: To assess the relationship between the type of chronic liver diseases
(CLDs), clinical severity and patients’ HRQoL. METHODS: A naturalistic, multicen-
tre study has been conducting to identify and test quality of care indicators. Adult
CLDs patients (age18 years) have been enrolling at gastroenterology unit of 3
Italian hospitals. We are collecting socio-demographic, clinical and HRQoL data
with the EQ-5D-3L. Patients are sub-grouped according to CLD type and to clinical
severity using the modified Child-Turcotte-Pugh score: with this instrument, pa-
tients are classified as non-cirrhotic, early cirrhotic (class A), advanced cirrhotic
(classes B and C). We conducted Kruskall-Wallis tests to assess relationship be-
tween EQ-5D-VAS score and disease type or severity score. RESULTS: Results are
based on data from 2,221 patients (67% male, median age62 years), classified into
the following subgroups: HCV or HBV chronic hepatitis (36.0%), compensated cir-
rhosis (CC, 23.5%), hepatocellular carcinoma (HCC, 19.8%), decompensated cirrho-
sis (DC, 13.5%), patients in evaluation or listed for liver transplant (LT, 7.2%). Non-
cirrhotic patients (HCV or HBV chronic hepatitis) had significantly (p0.001) higher
median VAS (80) than patients with any other CLD types (70). In contrast, patients
listed for LT had the lowest (p0.05) median VAS (65) and the highest proportion of
patients (58.1%) in Child class B-C. DC patients had a median VAS not significantly
different from that of HCC or CC patients (70 versus 70 and 73, respectively). On the
other hand, DC patients in child class A showed a significantly (p0.05) higher
median VAS (72.5) than HCC and CC patients in class B-C, who had a median VAS of
70 and 60, respectively. CONCLUSIONS: HRQoL of CLDs patients is significantly
related with the Child-Turcotte-Pugh severity score. These results could be useful
to understand the impact of the disease severity on patients’ HRQoL and guide
some decisions in clinical care.
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OBJECTIVES: Crohn’s disease is a chronic inflammatory bowel disease. Severe
Crohn’s disease management includes anti-Tumor Necrosis Factor (anti-TNF)
drugs differing from treatments used in early stages in terms of efficacy, safety and
convenience. To understand how specificities of anti-TNF treatments are per-
ceived by patients, the Satisfaction for Patients in Crohn’s disease (SPACE) ques-
tionnaire was developed to measure satisfaction with anti-TNF treatment in pa-
tients with severe Crohn’s disease. The study objectives were to finalise and
psychometrically validate the SPACE questionnaire. METHODS: An observational,
longitudinal, multicentre study was conducted in patients with severe, active
Crohn’s disease for which anti-TNF therapy was indicated. The 62-item pilot ver-
sion of the SPACE questionnaire was completed by patients at inclusion, 12 and 13
weeks after first anti-TNF injection. The final structure (i.e. grouping of items into
dimensions) was defined using multitrait and regression analyses. Psychometric
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